



Development and validation of the optimal circumferential resection margin in pathological T3 esophageal cancer: A multicenter retrospective study

メタデータ	言語: English						
	出版者:						
公開日: 2023-03-31							
キーワード (Ja):							
	キーワード (En):						
作成者: Haneda, Ryoma, Kikuchi, Hirotoshi, Na							
Yuka, Notsu, Akifumi, Booka, Eisuke, Murakami,							
Tomohiro, Matsumoto, Tomohiro, Mayanagi, Shul							
Morita, Yoshifumi, Hiramatsu, Yoshihiro, Tsubosa,							
	Yasuhiro, Takeuchi, Hiroya						
メールアドレス:							
	所属:						
URL	http://hdl.handle.net/10271/00004336						

1	Development and validation of the optimal circumferential resection margin in
2	pathological T3 esophageal cancer: A multicenter retrospective study
3	
4	Ryoma Haneda, MD ^{1,2} , Hirotoshi Kikuchi, MD, PhD ¹ , Yuka Nagakura, MD ³ , Akifumi
5	Notsu ⁴ , Eisuke Booka, MD, PhD ¹ , Tomohiro Murakami, MD, PhD ¹ , Tomohiro
6	Matsumoto, MD ¹ , Shuhei Mayanagi, MD, PhD ² , Yoshifumi Morita, MD, PhD ¹ , Yoshihiro
7	Hiramatsu, MD, PhD ^{1,5} , Yasuhiro Tsubosa, MD, PhD ² , Hiroya Takeuchi, MD, PhD ¹
8	
9	1. Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan
10	2. Division of Esophageal Surgery, Shizuoka Cancer Center, Shizuoka, Japan
11	3. Department of Diagnostic Pathology, Hamamatsu University School of Medicine,
12	Shizuoka, Japan
13	4. Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan
14	5. Department of Perioperative Functioning Care and Support, Hamamatsu University
15	School of Medicine, Shizuoka, Japan
16	
17	Corresponding author: Hirotoshi Kikuchi, MD, PhD.
18	Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama,
19	Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan
20	E-mail: kikuchih@hama-med.ac.jp
21	Phone: +81-53-435-2279; Fax: +81-53-435-2273
22	
23	
24	

1	Running head: Optimal surgical margin in T3 ESCC
2	
3	Conflict of Interest
4	The authors declare no conflicts of interest for this article.
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	

1 Synopsis

2	This study reported that the circumferential resection margin of 600 μ m, set
3	between the Royal College of Pathologists criteria and the College of American
4	Pathologists criteria, is optimal to predict locoregional recurrence for pathological T3
5	esophageal squamous cell carcinoma.
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	

1 Abstract

Background: The clinical significance of circumferential resection margin (CRM) in
esophageal squamous cell carcinoma (ESCC) remains unclear. Optimal CRM for
predicting the recurrence of pathological T3 ESCC was investigated.

5 Methods: Seventy-three patients were retrospectively investigated in the development 6 cohort. Patients were divided into CRM-negative and CRM-positive groups, and 7 clinicopathological factors and survival outcomes were compared between the groups. 8 The cut-off value was validated in another validation cohort (n = 99).

9 **Results:** Receiver operating characteristic analysis in the development cohort showed the 10 cut-off value of CRM was 600 µm. In the validation cohort, patients in the CRM-positive 11 group showed a significantly higher rate of locoregional recurrence (p = 0.006) and worse recurrence-free survival (RFS) (p < 0.001) than those in the CRM-negative group. 1213Multivariate analysis identified positive CRM as an independent predictive factor for 14 poor RFS (hazard ratio, 2.695; 95% confidence interval, 1.492–4.867; p = 0.001). The predictive value of our criteria of positive CRM for RFS was higher than that of the Royal 15College of Pathologists (RCP) and the College of American Pathologists (CAP) criteria. 16 Stratified analysis in the neoadjuvant chemotherapy groups also revealed that the rate of 1718 locoregional recurrence was higher in the CRM-positive group than in the CRM-negative 19 group both in the pathological N0 and N1–3 subgroups.

Conclusions: CRM of 600 µm can be the optimal cut-off value rather than the RCP and CAP criteria for predicting locoregional recurrence after esophagectomy. These results may support the impact of perioperative locoregional control of locally advanced ESCC.

23



1 Introduction

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide.¹ Transthoracic esophagectomy has been recognized as the standard treatment for esophageal squamous cell carcinoma (ESCC). The complete surgical removal of the invasive tumor is the primary aim of curative surgery for ESCC;²⁻⁴ however, advanced ESCCs often recur after R0 resection, with or without perioperative chemotherapy.

Some factors that can predict prognosis after resection include tumor size, tumor
grade, vessel involvement, and lymph node (LN) metastasis.^{5,6} Tumor infiltration of the
proximal or distal resection margins is associated with poor survival.^{7,8}

10 Regarding the vertical resection margin, the circumferential resection margin (CRM) involvement, which is reportedly a strong predictor of local recurrence in rectal 11 cancer, may be defined by two commonly used criteria in esophageal cancer.^{9,10} The 12Royal College of Pathologists (RCP) criteria define positive CRM as a tumor at or within 131 mm of the cut margin,¹¹ whereas the College of American Pathologists (CAP) criteria 14consider only the presence of a tumor at the cut margin as CRM-positive in esophageal 15cancer.¹² Although some studies have compared the prognostic significance of these two 16 CRM criteria, their usability remain controversial. 17

In this study, we hypothesized that there is an optimal cut-off value of CRM between 0 and 1 mm to predict locoregional recurrence and prognosis in patients with pathological T3 (pT3) ESCC. We then designed two cohorts at two independent institutions to determine the optimal cut-off value of CRM and validated its prognostic significance in ESCC patients.

23

24

1 Patients and methods

2 Study population

3 This study was a retrospective, observational clinical study that included two cohorts from two independent institutions: (i) Hamamatsu University School of Medicine 4 (HUSM, Shizuoka, Japan) and (ii) Shizuoka Cancer Center (ShCC, Shizuoka, Japan). $\mathbf{5}$ 6 This study included both a development cohort and a validation cohort. Eighty-three 7 patients with pT3 ESCC who underwent esophagectomy at HUSM between July 1, 2009, 8 and December 31, 2020, were recruited in the development cohort. In the validation cohort, 129 patients with pT3 ESCC who underwent esophagectomy at the ShCC between 9 10 January 1, 2011, and December 31, 2020, were recruited. All enrolled patients were 11 Japanese.

12All patients underwent preoperative esophagogastroduodenoscopy (EGD) and computed tomography (CT) from the neck to the pelvis to determine the clinical stage of 1314cancer. Positron emission tomography using 2-[18F] fluoro-2-deoxy-d-glucose (FDG-PET) and endoscopic ultrasound was also performed for some patients. Either current or 15former smokers were defined as smokers. Patients who regularly drank more than 14 g of 16 alcohol were defined as drinkers, according to the National Institutes of Alcohol Abuse 1718 and Alcoholism. The clinical and pathological stage were diagnosed based on the Union 19for International Cancer Control TNM classification of malignant tumors, 8th edition.¹³ Patients who met the following criteria were enrolled in this study: (1) age > 2020years, (2) Eastern Cooperative Oncology Group performance status of 0 to 1, (3) 21

histological diagnosis of ESCC by endoscopic biopsy, (4) no synchronous cancer, (5)
patients who underwent curative esophagectomy, (6) histologically proven invasion to
adventitia, (7) no metastasis to distant organs, and (8) no previous irradiation. Patients

were deemed ineligible for enrolment in this study based on the following exclusion criteria: salvage surgery, non-curative surgery, and positive proximal resection margin. Finally, the study population included 73 patients in the development cohort and 99 patients in the validation cohort.

5 All procedures were conducted in accordance with institutional and national 6 standards for human experimentation, as confirmed by the Ethics Committee of HUSM 7 (approval No: 21-062) and ShCC (approval No: 2965), and with the Declaration of 8 Helsinki of 1964 and its subsequent versions.

9

10 Treatment and postoperative complications

11 The treatment strategies were similar between the two institutions according to the 2017 esophageal cancer practice guidelines in Japan.^{2,3} Neoadjuvant chemotherapy 12(NAC) was performed as a standard treatment for patients with clinical stage II/III ESCC. 13The treatment regimen was a combination of cisplatin and 5-fluorouracil $(CF)^{14}$ or a 14 combination of docetaxel, cisplatin, and 5-fluorouracil.¹⁵ Transthoracic esophagectomy 15with 2- or 3-field LN dissection followed by gastric conduit reconstruction with cervical 16anastomosis was performed as a standard surgical procedure.^{16,17} Dissection of the 17supraclavicular LN was performed for patients with upper or middle thoracic ESCC and 18 for those with lower thoracic ESCC, with a clinical diagnosis of T2 or more.^{16,18} Although 19video-assisted thoracoscopic surgery is generally adopted in the thoracic approach, 20thoracotomy was performed for bulky primary tumors or for those possibly invading the 21surrounding organs, and for patients who refused thoracoscopy.¹⁶ Postoperative 22complications were evaluated for pneumonia, anastomotic leakage (AL), and surgical site 23infection (SSI) according to the Clavien–Dindo (C–D) classification. Pneumonia of C–D 24

grade 2 or higher and AL and SSI of C–D grade 3 or higher were defined as postoperative
 complications.^{19,20}

3

4 Assessment of CRM

5 All resected ESCC specimens were fixed in formalin and macroscopically 6 examined in detail by a certified pathologist at each institution. The specimens were 7 embedded in paraffin, and thin sections were stained with hematoxylin and eosin for 8 routine microscopic examination. The vertical cut edge of the resected specimens was 9 defined as CRM. The minimum distance of the CRM was measured in micrometers and 10 used to determine the CRM status (Supplementary Fig. 1).

11

12 Follow-up

The follow-up schedule was similar between the two institutions. Postoperative 1314 follow-up was performed using CT every six months and EGD every year for five years after surgery. When recurrence was suspected, the patients underwent FDG-PET and/or 15endoscopic examination with biopsy. The initial recurrent sites were classified into the 16 following three patterns: locoregional recurrence including a local recurrence defined as 17soft tissues newly detected at the circumferential region of the primary tumor and a lymph 18 19 node recurrence at Group 1 LNs around the primary tumor according to the Japanese Classification of Esophageal Cancer (JCEC) 11th edition;²¹ regional LN recurrence, 20defined as newly detected soft tissues indicative of recurrence at Group 2 LN metastases 21far from primary tumor in the mediastinal, abdominal, or cervical region, according to the 22JCEC 11th edition;²¹ and distant recurrence, defined as newly detected soft tissues 23indicative of recurrence at Group 3 or Group 4 LNs, according to the JCEC 11th edition,²¹ $\mathbf{24}$

9

1 or a hematogenous metastasis with organ tumor formation. Recurrence-free survival (RFS) was calculated from the day of surgery to the day of ESCC recurrence or death. $\mathbf{2}$ 3 Locoregional recurrence-free survival (LRRFS) was calculated from the day of surgery to the day of locoregional recurrence of ESCC or death. Overall survival (OS) was 4 calculated from the day of surgery to the day of death. Patients were followed up until $\mathbf{5}$ death, until 5 years after surgery, or until the end of the study, i.e., March 31, 2021. 6 7 Patients who died until 5 years, had interrupted follow-up, or under following up were 8 recognized as censored.

9

10 Statistical analyses

11 All statistical analyses were performed using IBM SPSS Statistics version 26 for Windows (Chicago, IL, USA). Receiver operating characteristic (ROC) analysis of CRM-1213based prediction of recurrence until 5 years after esophagectomy was performed to assess 14 the optimal cut-off value of the CRM. Medians and ranges were calculated, and differences were identified using Student's t-test. The Mann–Whitney U test was used for 15non-parametric analyses. Differences between each category were identified using the 16 Chi-squared test or Fisher's exact test. Survival curves were generated using the Kaplan-1718 Meier survival method and compared using the log-rank test. Hazard ratios (HRs) and 19 confidence intervals (CIs) were calculated, and univariate and multivariate analyses were 20performed using Cox proportional hazards regression models. The threshold for significance was set at p < 0.05. 21

22

23

24

1 Results

6

 $\mathbf{2}$

Determination of the cut-off values for CRM

ROC analysis of CRM-based prediction of recurrence in the development cohort
revealed that the area under the curve was 0.727. The cut-off value of the CRM was set
at 600 µm based on the peak point of the Youden index (sensitivity = 0.464, specificity =
0.844, Youden index = 0.308) (Supplementary Fig. 2).

7

8 Study flow diagram

9 Using this cut-off value, patients were divided into the CRM-negative group 10 (CRM > 600 μ m, n = 20) and the CRM-positive group (CRM \leq 600 μ m, n = 53) in the 11 development cohort (Supplementary Fig. 3). In the validation cohort, 46 and 53 patients 12 were classified into the CRM-negative and CRM-positive groups, respectively 13 (Supplementary Fig. 4). The median follow-up interval of all patients in the development 14 cohort was 28.6 months, while in the validation cohort, the median follow-up interval of 15 all patients was 23.3 months.

16

17 Patient characteristics

While comparing the clinical characteristics, no significant differences were found in the distribution of age, sex, smoking, drinking, tumor location, clinical stage, preoperative therapy, operation time, surgical approach, area of LN dissection, reconstruction organ, or postoperative complications between the CRM-negative and CRM-positive groups in either cohort (Supplementary Table 1). In the validation cohort, the rate of poorly differentiated ESCC in the biopsy specimens was higher in the CRMpositive group than in the CRM-negative group (37.7% vs. 15.2%, p = 0.040) $\mathbf{2}$

3 Clinical impact of the CRM status in the development cohort

Pathological findings were compared between the CRM-negative and CRMpositive groups in the development cohort (Table 1). The tumor diameter, rates of infiltrative growth-c (INFc), lymphatic vessel infiltration (LVI), blood vessel infiltration (BVI), pathological N (pN) status, and pathological stage were comparable between the two groups (Table 1).

9 The recurrence rate was significantly higher in the CRM-positive group than in 10 the CRM-negative group (71.7 % vs. 35.0 %, p = 0.007). Locoregional recurrence was 11 more frequently observed in the CRM-positive group than in the CRM-negative group 12 (41.5 % vs. 2.0 %, p = 0.002), whereas the incidence of regional LN recurrence and distant 13 recurrence was comparable between the two groups (Table 1).

14 RFS was significantly worse in the CRM-positive group than in the CRM-15 negative group (median survival time [MST]; 10.3 vs. 32.7 months, p = 0.005), whereas 16 no difference was seen in OS between the two groups (MST; 21.0 vs. 36.7 months, p =17 0.246) (Fig. 1). Multivariate analyses identified positive CRM as an independent 18 predictive factor of poor RFS (p = 0.037, [HR, 2.482; 95 % CI, 1.056–5.832]) (Table 2).

19

20 Validation of the present CRM status

The developed model was then used to predict risks in the validation cohort. Regarding the pathological findings, the rates of INFc, positive LVI, and positive BVI were significantly higher in the CRM-positive group than in the CRM-negative group (INFc, 22.6 % vs. 6.5 %, p = 0.022; LVI, 69.8 % vs. 43.5 %, p = 0.014; BVI, 86.8 % vs. 1 65.2 %, p = 0.016, respectively). There was no significant difference in pN status and 2 pathological stage between the two groups (Table 1).

Consistent with the development cohort, the recurrence rate in the validation cohort was significantly higher in the CRM-positive group than in the CRM-negative group (64.2 % vs. 37.0 %, p = 0.009). Regarding the pattern of initial recurrence, locoregional recurrence was more frequently observed in the CRM-positive group than in the CRM-negative group (32.1 % vs. 8.7 %, p = 0.006). Furthermore, the rate of distant recurrence was also higher in the CRM-positive group than in the CRM-negative group (47.2 % vs. 17.4 %, p = 0.003) (Table 1).

Patients in the CRM-positive group had significantly worse RFS and OS than those in the CRM-negative group (MST; RFS, 9.9 vs. 23.3 months, p < 0.001 and OS, 18.7 vs. 36.1 months, p = 0.002) (Fig. 2). Consistent with the development cohort, multivariate analyses identified positive CRM as an independent predictive factor for poor RFS (p = 0.001, HR, 2.695; 95 % CI, 1.492–4.867) (Table 2).

15

16 **Predictive factors of positive CRM**

To identify preoperative clinicopathological factors predictive of positive CRM, cox regression analyses for positive CRM were performed in the validation cohort (Supplementary Table 2). In univariate and multivariate analyses, poorly differentiated histology (p = 0.027, HR, 2.647; 95 % CI, 1.119–6.263) and macroscopic Type 1 or Type 3 (p = 0.026, HR, 3.124; 95 % CI, 1.148–8.500) were identified as predictive factors of positive CRM (Supplementary Table 2).

23

24 Comparison of the RCP, CAP, and our criteria

1	The clinical impact of our criteria was compared with the two conventional
2	criteria, i.e., the RCP criteria and CAP criteria, using the data from the validation cohort.
3	The recurrence rate in the CRM-positive group was significantly higher than that in the
4	CRM-negative group according to the RCP criteria (61.7% vs. 35.9%, $p = 0.014$) and
5	CAP criteria (86.7% vs. 45.2%, $p = 0.004$). Locoregional recurrence was more frequently
6	observed in the CRM-positive group than in the CRM-negative group according to the
7	RCP criteria (30.0 % vs. 7.7 %, $p = 0.011$), whereas there was no difference between the
8	two groups according to the CAP criteria (40.0 % vs. 17.9 %, $p = 0.082$) (Supplementary
9	Table 3). The sensitivities of the prediction of locoregional recurrence were 0.857, 0.810
10	and 0.286 in the RCP criteria, our criteria and the CAP criteria. The specificities of
11	prediction of locoregional recurrence were 0.462, 0.538 and 0.885, respectively. The false
12	positive rate was 0.538, 0.462 and 0.115, and the Youden index was 0.319, 0.348 and
13	0.171 in the RCP criteria, our criteria and the CAP criteria, respectively.

According to the RCP criteria, patients in the CRM-positive group had significantly worse RFS and OS than those in the CRM-negative group (MST; RFS, 10.4 vs. 28.5 months, p < 0.001 and OS, 18.7 vs. 40.2 months, p = 0.004). In contrast, according to the CAP criteria, patients in the CRM-positive group had significantly worse RFS than those in the CRM-negative group (MST, 9.5 vs. 19.2 months, p < 0.001), whereas there was no significant difference in OS between the two groups (MST, 15.4 vs. 24.2 months, p = 0.190).

To evaluate the usefulness of our criteria, patients in the validation cohort were divided into four groups according to CRM status; 0 μ m, 0–600 μ m, 600–1000 μ m, and > 1000 μ m (Supplementary Fig. 5). Patients in the 0–600 μ m group had significantly worse RFS and OS than those in the 600–1000 μ m group (MST; RFS, 10.3 vs. 22.5 1 months, p = 0.006 and OS, 18.5 vs. 32.2 months, p = 0.013). Furthermore, there was no 2 difference in OS and RFS between the 0–600 µm and 0 µm groups, and there was also no 3 difference in OS and RFS between 600–1000 µm and > 1000 µm groups (Supplementary 4 Fig. 5).

5 Univariate analysis demonstrated that the HR of positive CRM for poor RFS was 6 2.928 (95% CI, 1.453–5.902, p = 0.003) in the RCP criteria, 3.167 (95% CI, 1.778–5.644, 7 p < 0.001) in our criteria, and 2.236 (95% CI, 1.117–4.475, p = 0.023) in the CAP criteria 8 (Table 3).

9

10

Survival impact of the CRM adjusted for neoadjuvant chemotherapy and pN status

11 To evaluate the prognostic value of CRM irrespective of the confounding influence of LN metastasis, stratified analyses adjusted for LN metastasis and NAC were 1213performed. All enrolled patients in the two cohorts were classified into four groups 14according to the status of NAC and pN: non-NAC and pN0 group (n = 10), non-NAC and pN1-3 group (n = 22), NAC and pN0 group (n = 21), and NAC and pN1-3 groups (n = 21) 15119). In the non-NAC group, the incidence of total recurrence was similar between the 16CRM-positive and CRM-negative groups regardless of the pN status (pN0 groups, p =171.000 and pN1–3 groups, p = 1.000). However, the incidence of locoregional recurrence 18 19in the NAC group was higher in the CRM-positive group than in the CRM-negative group, both in the pN0 and pN1–3 subgroups (pN0 groups, 37.5% vs. 0.0%, p = 0.042 and pN1– 203 groups, 39.7% vs. 9.8%, p = 0.001, respectively) (Table 4). 21Next, we analyzed the survival impact of CRM-positivity according to pN status 22

in patients treated with NAC. Although there was no significant difference, patients in the CRM-positive group tended to show worse RFS (MST; 26.1 vs. 54.7 months, p = 0.093)

1	and OS (MST; 32.4 vs. 54.7 months, $p = 0.087$) in the pN0 subgroups (Fig. 3a, 3c).
2	Furthermore, LRRFS was significantly worse in the CRM-positive group than in the
3	CRM-negative group in the pN0 subgroups (MST; 26.1 vs. 54.7 months, $p = 0.015$) (Fig.
4	3b). Furthermore, within the pN1-3 subgroup, patients in the CRM-positive group
5	showed significantly worse RFS (MST; RFS, 10.2 vs. 28.5 months, $p < 0.001$), LRRFS
6	(LRRFS, 14.5 vs. 34.9 months, <i>p</i> < 0.001), and OS (OS, 20.3 vs. 38.9 months, <i>p</i> < 0.001)
7	than those in the CRM-negative group (Fig. 3d, 3e, 3f).
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	

Discussion 1

 $\mathbf{2}$

3

This study demonstrated that patients with a CRM \leq 600 µm (CRM-positive) showed worse RFS and higher rates of locoregional recurrence than those with CRM >

600 µm (CRM-negative), and validated the cut-off value of CRM in another independent 4 cohort. Furthermore, CRM-positivity according to our criteria, had a stronger correlation $\mathbf{5}$ with locoregional recurrence compared to the RCP and CAP criteria in the validation 6 7 cohort. These results suggested that the optimal CRM was $600 \,\mu\text{m}$, which was set between 8 the RCP and CAP criteria, to predict locoregional recurrence after esophagectomy for 9 pT3 ESCC.

10 In the validation cohort, the incidence of locoregional recurrence was higher in 11 the CRM-positive group than in the CRM-negative group according to the RCP criteria, 12while there was no difference between the two groups according to the CAP criteria. 13Positive CRM according to the RCP criteria showed higher sensitivity to locoregional 14 recurrence compared to our criteria; however, the false-positive rate was higher. The Youden index, which indicates predictive ability, was the highest in our criteria among 15the three criteria. In the survival analysis, our criteria showed the highest HR for 16 predicting poor RFS. Moreover, our criteria clearly separated the survival curve in the 17ambiguous range of CRM between 0 and 1000 µm. These results demonstrate that our 18 19 criteria are the most useful as factors for predicting recurrence. Some studies have reported the prognostic impact of CRM involvement in esophageal cancer.²²⁻²⁷ Most 20studies have compared the CAP criteria with the RCP criteria, and the results remain 21controversial. Okada et al. reported that positive CRM according to the CAP criteria 22significantly affected the OS and RFS of pT3 ESCC patients.²² However, Ghadban et al. 23reported that there was no correlation, neither according to the CAP nor RCP criteria, with 24

local recurrence and prognosis in esophageal cancer.²⁴ If the CRM of tumor specimens is 1 identified between 0 and 1000 µm microscopically after esophagectomy, surgeons often $\mathbf{2}$ 3 face difficulties in the selection of proper therapeutic options because little is known about the cut-off value for positive CRM. Some single cohort studies proposed a new cut-off 4 value of CRM at 500–600 µm, and CRM-positive patients showed worse OS,^{27,28} which $\mathbf{5}$ is consistent with the results of our study. As per our knowledge, our study is the first to 6 investigate the optimal cut-off value of CRM between the RCP and CAP criteria in pT3 7 8 ESCC, and to validate its usability in another independent cohort.

9 This study demonstrated that tumors in the CRM-positive group were more 10 frequently accompanied by lymphatic and vascular infiltration. Tsutsui et al. 11 pathologically examined the specimens, and reported five types of accessory lesions that existed beyond the main lesion: intraepithelial carcinoma, subepithelial direct extension, 12intramural metastasis, lymphatic invasion, and vascular invasion.²⁹ The occurrence of 1314these accessory lesions increased in cases with tumor invasion into the adventitia or deeper. High invasiveness to lymphatic and vascular tissue in pT3, especially close to the 15surgical margin, led to the discovery of cancer remnants microscopically.^{29,30} 16

According to the 2017 esophageal cancer practice guidelines in Japan, the 17standard treatment for clinical stage II/III ESCC is NAC followed by radical 18 esophagectomy.^{2,3} Stratified analysis in the NAC groups revealed that the rate of 19 20locoregional recurrence was higher in the CRM-positive group than in the CRM-negative group, both in the pN0 and pN1-3 subgroups. Furthermore, the CRM-positive group 21showed worse LRRFS than the CRM-negative group in both the pN0 and pN1-3 2223subgroups. These results suggest that our criteria could provide the optimal cut-off value of CRM for predicting locoregional recurrence. To date, no studies have evaluated the 24

1 survival impact of CRM in patients who underwent standard treatment for ESCC. Our study evaluated the prognostic value of CRM by eliminating the influence of pN $\mathbf{2}$ 3 metastasis status. These results suggest the importance of adjuvant chemotherapy, radiotherapy or chemoradiotherapy for postoperative local control in CRM-positive cases. 4 A recent phase 3 clinical trial CheckMate 577 showed that postoperative immunotherapy $\mathbf{5}$ with nivolumab improved disease-free survival in patients with ESCC and esophageal-6 7 gastric junction cancer who received neoadjuvant chemoradiotherapy (NACRT) followed by surgery.³¹ Adjuvant immunotherapy has become a treatment option of advanced ESCC, 8 9 although the clinical effect of immunotherapy as adjuvant treatment after surgery 10 following NAC remains controversial.

11 A previous study reported that pT3 was an independent predictive factor for poor OS and progression-free survival in patients who received NAC followed by surgery for 1213clinical stage II/III ESCC, suggesting the necessity of additional perioperative therapy for pT3 ESCC.³² In Western countries, where adenocarcinoma accounts for the vast majority 14 of esophageal cancers, chemoradiation is often performed as either neoadjuvant or 1516 perioperative treatment, and the association between perioperative chemoradiotherapy and complete resection margin has been reported.³³ In this setting, most tumors after 17NACRT showed a high pathological regression rate, leading to securing the safe CRM 18 and accomplishing a high complete resection rate.³³ In contrast, our results suggest that 19 20NAC consisting of CF might be insufficient to control locoregional recurrence in pT3 ESCC, especially close to surgical margin. In a multivariate analysis, poorly 21differentiation and macroscopic classification of Type 1 or 3 were identified as predictive 22factors for positive CRM. These results may contribute to the patient selection to intensive 23neoadjuvant therapies such as NACRT and more intensive NAC to improve the local $\mathbf{24}$

1 control and to increase the complete resection rate in T3 ESCC.

2	This study has some limitations. First, this was a retrospective study. However,
3	in terms of CRM, prospective studies are difficult to plan. Second, the treatment strategies
4	of ESCC, including NAC regimen and perioperative management, slightly differed
5	between the institutions in this multicenter study, which could have affected the results.
6	However, both participating institutions were high-volume centers with the ability to
7	deliver high quality care.
8	A major strength of this study is that it reported the optimal cut-off value of CRM
9	set between the RCP criteria and the CAP criteria in thoracic ESCC, the consistency of
10	which was validated in another independent cohort.
11	In conclusion, a CRM of 600 μ m has the potential to become the optimal cut-off,
12	value rather than the RCP and CAP criteria, to predict locoregional recurrence after
13	esophagectomy for ESCC. These results may support the impact of perioperative
14	locoregional control of locally advanced ESCC.
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	

1 Acknowledgements

2 The authors gratefully acknowledge Satoshi Baba, the pathologist of the HUSM. 3

4 Human rights statement and informed consent

All procedures were conducted in accordance with institutional and national standards on human experimentation, as confirmed by the ethics committee of Hamamatsu University School of Medicine (approval number; 21-062) and Shizuoka Cancer Center (approval number; 2965), and with the Declaration of Helsinki of 1964 and its later versions.

10

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.

2. Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24.

3. Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25-43.

4. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545-553.

5. Khan OA, Fitzgerald JJ, Soomro I, Beggs FD, Morgan WE, Duffy JP. Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer. Br J Cancer. 2003;88:1549-1552.

 Veeramachaneni NK, Zoole JB, Decker PA, Putnam JB, Jr., Meyers BF. Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial. Ann Thorac Surg. 2008;86:418-421.

7. Kato H, Tachimori Y, Watanabe H, et al. Anastomotic recurrence of oesophageal squamous cell carcinoma after transthoracic oesophagectomy. Eur J Surg. 1998;164:759-764.

8. Mariette C, Castel B, Balon JM, Van Seuningen I, Triboulet JP. Extent of oesophageal resection for adenocarcinoma of the oesophagogastric junction. Eur J Surg Oncol. 2003;29:588-593.

9. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26:350-357. 10. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26:303-312.

11.The Royal College of Pathologists.Standards and datasets for reporting cancersdataset for histopathological reporting of oesophageal and gastric carcinoma.October 2019.Availableat:<a href="https://www.rcpath.org/uploads/assets/f8b1ea3d-5529-4f85-984c8d4d8556e0b7/068e9093-0aea-4316-bdd49771564784b9/g006-dataset-for-984c8d4d8556e0b7/068e9093-0aea-4316-bdd49771564784b9/g006-dataset-for-

histopathological-reporting-of-oesophageal-and-gastric-carcinoma.pdf. Accessed November 2nd, 2021.

12. College of American Pathologists. Protocol for the examination of specimens from patients with carcinoma of the esophagus. Available at: https://documents.cap.org/protocols/cp-esophagus-17protocol-4000.pdf. Accessed November 2nd, 2021.

13. Brierley JD GM, Wittekind C. TNM Classification of Malignant Tumors, Eight Edition. 2017.

14. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68-74.

15. Hara H, Tahara M, Daiko H, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104:1455-1460.

16. Kikuchi H, Hiramatsu Y, Matsumoto T, et al. The hybrid position is superior to the prone position for thoracoscopic esophagectomy with upper mediastinal lymphadenectomy. Ann Laparosc Endosc Surg. 2020;5:13-13.

17. Booka E, Kikuchi H, Haneda R, et al. Short-term Outcomes of Robot-assisted Minimally Invasive Esophagectomy Compared With Thoracoscopic or Transthoracic Esophagectomy. Anticancer Res. 2021;41:4455-4462.

18. Yamashita K, Watanabe M, Mine S, et al. Minimally invasive esophagectomy attenuates the postoperative inflammatory response and improves survival compared with open esophagectomy in patients with esophageal cancer: a propensity score matched analysis. Surg Endosc. 2018;32:4443-4450.

19. Kawata S, Hiramatsu Y, Shirai Y, et al. Multidisciplinary team management for prevention of pneumonia and long-term weight loss after esophagectomy: a single-center retrospective study. Esophagus. 2020;17:270-278.

20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.

21. Japan Esophageal S. Japanese Classification of Esophageal Cancer, 11th Edition: partI. Esophagus. 2017;14:1-36.

22. Okada N, Fujii S, Fujita T, et al. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy. Surgery. 2016;159:441-450.

Evans R, Bundred JR, Kaur P, Hodson J, Griffiths EA. Meta-analysis of the influence of a positive circumferential resection margin in oesophageal cancer. BJS Open. 2019;3:595-605.

24. Ghadban T, Reeh M, Koenig AM, et al. Prognostic Significant or Not? The positive circumferential resection margin in esophageal cancer: Impact on local recurrence and overall survival in patients without neoadjuvant treatment. Ann Surg. 2017;266:988-994.

25. Depypere L, Moons J, Lerut T, et al. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy. Dis Esophagus. 2017;31: 1-8.

26. Liu CY, Hsu PK, Hsu HS, et al. Prognostic impact of circumferential resection margin in esophageal cancer with or without neoadjuvant chemoradiotherapy. Dis Esophagus. 2020;33:1-7.

27. Lee GD, Lee SE, Kim KM, et al. New 3-tiered circumferential resection margin criteria in esophageal squamous cell carcinoma. Ann Surg. 2015;262:965-971.

28. Yang YS, Wang YC, Deng HY, et al. Prognostic value of circumferential resection margin in T3N0M0 esophageal squamous cell carcinoma. Ann Transl Med. 2018;6:303.

29. Tsutsui S, Kuwano H, Watanabe M, Kitamura M, Sugimachi K. Resection margin for squamous cell carcinoma of the esophagus. Ann Surg. 1995;222:193-202.

30. Huang Q, Luo K, Chen C, et al. Identification and validation of lymphovascular invasion as a prognostic and staging factor in node-negative esophageal squamous cell carcinoma. J Thorac Oncol. 2016;11:583-592.

31. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384:1191-1203.

32. Kataoka K, Takeuchi H, Mizusawa J, et al. Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: Exploratory analysis of JCOG9907. Ann Surg. 2017;265:1152-1157.

33. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-2084.

Figure Legends

Fig. 1 Kaplan–Meier analysis in the two cohort. **a**. Comparison of recurrence-free survival between the CRM-negative and CRM-positive groups in the development cohort. **b**. Comparison of overall survival between the CRM-negative and CRM-positive groups in the development cohort. **c**. Comparison of recurrence-free survival between the CRM-negative and CRM-negative and CRM-positive groups in the validation cohort. **d**. Comparison of overall survival between the CRM-negative and CRM-negative and CRM-positive groups in the validation cohort. **d**. Comparison of overall survival between the CRM-negative and CRM-negative and CRM-positive groups in the validation cohort.

Fig. 2 Kaplan–Meier analysis in the validation cohort. a. Comparison of recurrence-free survival between the CRM-negative and CRM-positive groups. b. Comparison of overall survival between the CRM-negative and CRM-positive groups.

Fig. 3 Stratified analysis of survival of patients treated with neoadjuvant chemotherapy according to the pN status. **a**. Comparison of recurrence-free survival between the CRM-negative and CRM-positive groups in pN0 ESCC patients. **b**. Comparison of locoregional recurrence-free survival between the CRM-negative and CRM-positive groups in pN0 ESCC patients. **c**. Comparison of overall survival between the CRM-negative and CRM-negative and CRM-positive groups in pN0 ESCC patients. **d**. Comparison of recurrence-free survival between the CRM-negative and CRM-positive groups in pN1–3 ESCC patients. **e**. Comparison of locoregional recurrence-free survival between the CRM-negative and CRM-positive groups in pN1–3 ESCC patients. **f**. Comparison of overall survival between the CRM-negative and CRM-positive groups in pN1–3 ESCC patients. **f**. Comparison of overall survival between the CRM-negative and CRM-positive groups in pN1–3 ESCC patients.

Fig. 1





b

Fig. 2





b



Table 1 Comparison of pathologica	al findings between th	e CRM-negative and	CRM-posit	tive groups in the t	wo cohort			
	Deve	Development cohort Validation cohort						
	CRM-negative CRM-positive p value			CRM-negative	CRM-positive	p		
	group	group		group	group	value		
	n = 20	n = 53		n = 46	n = 53			
Tumor diameter, mm †	37.5 (25.0–70.0)	45 (23.0–150.0)	0.078	48.0 (4.0-95.0)	45.0 (25.0-120.0)	0.679		
INF (%)			0.766			0.022		
А	0 (0.0%)	2 (3.8%)		2 (4.3%)	0 (0.0%)			
В	20 (100.0%)	48 (90.6%)		41 (89.1%)	41 (77.4%)			
С	0 (0.0%)	3 (5.7%)		3 (6.5%)	12 (22.6%)			
Lymphatic vessel infiltration (%)			0.060			0.014		
(-)	6 (30.0%)	5 (9.4%)		26 (56.5%)	16 (30.2%)			
(+)	14 (70.0%)	48 (90.6%)		20 (43.5%)	37 (69.8%)			
Blood vessel infiltration (%)			0.072			0.016		
(-)	2 (10.0%)	0 (0.0%)		16 (34.8%)	7 (13.2%)			
(+)	18 (90.0%)	53 (100.0%)		30 (65.2%)	46 (86.8%)			
Pathological N status (%)			0.173			0.105		
pN0	5 (25.0%)	5 (9.4%)		13 (28.3%)	7 (13.2%)			
pN1	6 (30.0%)	10 (18.9%)		18 (39.1%)	18 (34.0%)			
pN2	5 (25.0%)	18 (34.0%)		12 (26.1%)	18 (34.0%)			
pN3	4 (20.0%)	20 (37.7%)		3 (6.5%)	10 (18.8%)			
Pathological stage, TNM 8th (%)			0.227			0.186		
Stage IIB	5 (25.0%)	5 (9.4%)		13 (28.3%)	7 (13.2%)			

Stage IIIB	10 (50.0%)	25 (47.2%)		29 (63.0%)	36 (67.9%)	
Stage IVA	4 (20.0%)	13 (24.5%)		3 (6.5%)	8 (15.1%)	
Stage IVB	1 (5.0%)	10 (18.9%)		1 (2.2%)	2 (3.8%)	
Initial recurrent site* (%)						
Locoregional recurrence	1 (5.0%)	22 (41.5%)	0.002	4 (8.7%)	17 (32.1%)	0.006
Regional LN recurrence	3 (15.0%)	19 (35.8%)	0.096	9 (19.6%)	7 (13.2%)	0.424
Distant recurrence	6 (30.0%)	22 (41.5%)	0.428	8 (17.4%)	25 (47.2%)	0.003

†Values were presented as median (range).

* Multiple sites of recurrence existed in some patients.

CRM, circumferential resection margin; INF, infiltrative growth; LN, lymph node

Table 2 Prognostic factors for poor recurrence-free survival in the two cohorts										
Development cohort										
Univariate analysis Multivariate analysis										
	HR	<i>p</i> value	95% CI	HR	<i>p</i> value	95% CI				
Age	1.001	0.949	0.968-1.035							
Anastomotic leakage, +	1.134	0.819	0.385-3.338							
Pneumonia, +	1.263	0.621	0.500-3.190							
Lymphatic vessel infiltration, +	2.318	0.109	0.828-6.486	1.250	0.689	0.419-3.733				
Blood vessel infiltration, +	0.439	0.441	0.054-3.561							
CRM, positive	3.014	0.008	1.338-6.792	2.482	0.037	1.056-5.832				
pStage, III+IV	3.367	0.043	1.039–10.912	2.535	0.130	0.761-8.442				

Validation cohort							
		Univariate a	nalysis	Multivariate analysis			
	HR	<i>p</i> value	95% CI	HR	<i>p</i> value	95% CI	
Age	0.990	0.548	0.957-1.023				
Anastomotic leakage, +	1.231	0.553	0.619–2.446				
Pneumonia, +	1.265	0.418	0.716-2.233				
INF, c	1.527	0.235	0.759-3.073				
Lymphatic vessel infiltration, +	2.436	0.002	1.374-4.319	1.751	0.065	0.965-3.178	
Blood vessel infiltration, +	2.045	0.034	1.056-3.960	1.328	0.427	0.659–2.676	
CRM, positive	3.167	< 0.001	1.778–5.644	2.695	0.001	1.492–4.867	

pStage, III+IV	3.031	0.018	1.209-7.600	2.294	0.083	0.898-5.862
----------------	-------	-------	-------------	-------	-------	-------------

CI, confidence interval; CRM, circumferential resection margin; HR, hazard ratio; INF, infiltrative growth; pStage, pathological stage

Table 3 Comparison of the predictive values of positive CRM for poor recurrence-free survival among three different criteria in the validation cohort

	No. of CRM-positive patients (%)	Univariate analysis		
		HR	<i>p</i> value	95% CI
RCP criteria (cut-off, 1000 μm)	60 (60.6%)	2.928	0.003	1.453-5.902
Our criteria (cut-off, 600 µm)	53 (53.5%)	3.167	< 0.001	1.778-5.644
CAP criteria (cut-off, 0 µm)	15 (15.2%)	2.236	0.023	1.117-4.475

CAP, College of American Pathologists; CI, confidence interval; CRM, circumferential resection margin; HR, hazard ratio; RCP, Royal

College of Pathologists

Table 4 Relationship between	our criteria and recurre	ent site adjusted for n	eoadjuvant ch	emotherapy and path	nological N status			
No neoadjuvant chemotherapy								
		pN0		pN1-3				
	CRM-negative	CRM-positive	<i>p</i> value	CRM-negative	CRM-positive	<i>p</i> value		
	group	group		group	group			
	n = 5	n = 5		n = 7	n = 15			
Initial recurrent site* (%)								
Locoregional recurrence	0 (0.0%)	2 (40.0%)	0.444	1 (14.3%)	3 (20.0%)	1.000		
Regional LN recurrence	1 (20.0%)	1 (20.0%)	1.000	3 (42.9%)	5 (33.3%)	1.000		
Distant recurrence	0 (0.0%)	0 (0.0%)	1.000	1 (14.3%)	6 (40.0%)	0.350		
Neoadjuvant chemotherapy								
		pN0			pN1-3			
	CRM-negative	CRM-positive	<i>p</i> value	CRM-negative	CRM-positive	<i>p</i> value		
	group	group		group	group			
	n = 13	n = 8		n = 41	n = 78			
Initial recurrent site* (%)								
Locoregional recurrence	0 (0.0%)	3 (37.5%)	0.042	4 (9.8%)	31 (39.7%)	0.001		
Regional LN recurrence	1 (7.7%)	2 (25.0%)	0.531	7 (17.1%)	18 (23.1%)	0.488		
Distant recurrence	1 (7.7%)	2 (25.0%)	0.531	13 (31.7%)	38 (48.7%)	0.083		

*Multiple sites of recurrence existed in some patients

CRM, circumferential resection margin; LN, lymph node; pN, pathological N

Supplementary Table 1 Patient characteristics									
	Development cohort			Validation cohort					
	CRM-negative group n = 20	CRM-positive group n = 53	<i>p</i> value	CRM-negative group n = 46	CRM-positive group n = 53	<i>p</i> value			
Age (median, years) †	68 (50-76)	68 (40-82)	0.867	68 (36–79)	70 (35–80)	0.771			
Sex (%)			1.000			0.798			
Male	18 (90.0%)	47 (88.7%)		37 (80.4%)	44 (83.0%)				
Female	2 (10.0%)	6 (11.3%)		9 (19.6%)	9 (17.0%)				
Smoker (%)	17 (85.0%)	48 (90.6%)	0.676	45 (97.8%)	52 (98.1%)	1.000			
Drinker (%)	19 (95.0%)	51 (96.2%)	1.000	44 (95.7%)	49 (92.5%)	0.683			
Tumor location (%)			0.094			0.481			
Ut	1 (5.0%)	4 (7.5%)		4 (8.7%)	5 (9.4%)				
Mt	7 (35.0%)	32 (60.4%)		24 (52.2%)	21 (39.6%)				
Lt	12 (60.0%)	17 (32.1%)		18 (39.1%)	27 (50.9%)				
Macroscopic classification (%)			0.823			0.671			
Type1	2 (10.0%)	7 (13.2%)		5 (10.9%)	3 (5.7%)				
Type2	9 (45.0%)	18 (34.0%)		26 (56.5%)	32 (60.4%)				
Туре3	9 (45.0%)	27 (50.9%)		15 (32.6%)	18 (34.0%)				
Type4	0 (0.0%)	1 (1.9%)		0 (0.0%)	0 (0.0%)				
Histological differentiation (%)			0.164			0.040			
poorly	1 (5.0%)	12 (22.6%)		7 (15.2%)	20 (37.7%)				

moderate	10 (50.0%)	18 (34.0%)		29 (63.0%)	26 (49.1%)	
well	9 (45.0%)	23 (43.4%)		10 (21.7%)	7 (13.2%)	
Clinical Stage, TNM 8th (%)			0.327			0.617
Stage I	1 (5.0%)	0 (0.0%)		10 (21.7%)	8 (15.1%)	
Stage II	8 (40.0%)	17 (32.1%)		29 (63.0%)	40 (75.5%)	
Stage III	10 (50.0%)	34 (64.2%)		6 (13.0%)	4 (7.5%)	
Stage IVA	1 (5.0%)	2 (3.8%)		1 (2.2%)	1 (1.9%)	
Preoperative therapy (%)			0.509			0.426
None	5 (25.0%)	9 (17.0%)		6 (13.3%)	11 (20.8%)	
NAC	15 (75.0%)	44 (83.0%)		39 (86.7%)	42 (79.2%)	
Surgical approach (%)			0.792			0.674
Thoracotomy	13 (65.0%)	32 (60.4%)		29 (63.0%)	36 (67.9%)	
Thoracoscopy	7 (35.0%)	21 (39.6%)		17 (37.0%)	17 (32.1%)	
LN dissection (%)			1.000			0.632
2-field	3 (15.0%)	9 (17.0%)		9 (19.6%)	13 (24.5%)	
3-field	17 (85.0%)	44 (83.0%)		37 (80.4%)	40 (75.5%)	
Reconstruction organ (%)			0.676			0.412
Gastric conduit	17 (85.0%)	48 (90.6%)		42 (91.3%)	51 (96.2%)	
Colon conduit	3 (15.0%)	5 (9.4%)		4 (8.7%)	2 (3.8%)	
Operation time (median, min) †	559 (441–763)	558 (347–927)	0.595	423 (316–671)	434 (258–615)	0.388
Postoperative complications (%)						
AL, C-D grade ≥ 3	2 (10.0%)	9 (17.0%)	0.716	8 (17.4%)	10 (18.9%)	1.000
Pneumonia, C-D grade ≥ 2	7 (35.0%)	13 (24.5%)	0.390	12 (26.1%)	16 (30.2%)	0.823

SSI, C-D grade ≥ 3 0 (0.0%) 1 (1.9%) 1.000 4 (8.7%) 5 (9.4%) 1.000

† Values are presented as median (range)

AL; anastomotic leakage; C-D, Clavien-Dindo classification; CRM, circumferential resection margin; LN, lymph node; Lt, lower thoracic esophagus (thoracic esophagus from inferior half between tracheal bifurcation and esophagogastric junction); Mt, middle thoracic esophagus (superior half between tracheal bifurcation and esophagogastric junction); NAC, neoadjuvant chemotherapy; SSI, surgical site infection; Ut, upper thoracic esophagus (from superior margin of the sternum to tracheal bifurcation)

Supplementary Table 2 Chnicopathological factors to predict positive CRM in the validation conort									
	Univariate analysis			Ν	analysis				
	OR	<i>p</i> value	95% CI	OR	<i>p</i> value	95% CI			
Age	0.998	0.915	0.954-1.043						
Sex, Male	1.189	0.740	0.428-3.305						
Histological differentiation, poorly	3.377	0.015	1.270-8.976	2.647	0.027	1.119-6.263			
Tumor location, Ut	1.094	0.899	0.276-4.341						
Macroscopic classification, Type1 and 3	0.352	0.015	0.152-0.813	3.124	0.026	1.148 - 8.500			
NAC, +	0.587	0.337	0.198-1.740						
Thoracic approach, Thoracoscopy	1.241	0.610	0.541 - 2.851						

Supplementary Table 2 Clinicanathelegical factors to mediat negitive CPM in the validation achart

CRM, circumferential resection margin; CI, confidence intervals; NAC, Neoadjuvant chemotherapy; OR, Odds ratio; Ut, upper thoracic

esophagus (from superior margin of the sternum to tracheal bifurcation)

Supplementary Table 3 Comparison between the RCP and CAP criteria in the validation cohort								
	The RCP criteria			The CAP criteria				
	CRM-negative	CRM-positive	<i>p</i> value	CRM-negative	CRM-positive	<i>p</i> value		
	group	group		group	group			
	n = 39	n = 60		n = 84	n = 15			
Initial recurrent site* (%)								
Locoregional recurrence	3 (7.7%)	18 (30.0%)	0.011	15 (17.9%)	6 (40.0%)	0.082		
Regional LN recurrence	6 (15.4%)	10 (16.7%)	1.000	14 (16.7%)	2 (13.3%)	1.000		
Distant recurrence	8 (20.5%)	25 (41.7%)	0.032	23 (27.4%)	10 (66.7%)	0.006		

*Multiple sites of recurrence existed in some patients

CAP, College of American Pathologists; CRM, circumferential resection margin; LN, lymph node; RCP, Royal College of Pathologists

Supplementary Fig. 1



Supplementary Fig. 1 Microscopic measurement of the circumferential resection margin (CRM) of the resected specimens which were

stained with hematoxylin and eosin. **a**. CRM > 1000 μ m **b**. CRM between 600 and 1000 μ m **c**. CRM between 0 and 600 μ m **d**. CRM 0

μm.





Supplementary Fig. 2 The receiver operating characteristic (ROC) curve of circumferential resection margin for predicting recurrence in

the development cohort. The area under the curve was 0.727. The cut-off value was set at 600 μ m (sensitivity = 0.464, specificity = 0.844;

Youden index = 0.308, dashed line)





Supplementary Fig. 3 The study flow diagram of the development cohort. CRM, circumferential resection margin.





Supplementary Fig. 4 The study flow diagram of the validation cohort. CRM, circumferential resection margin.





Supplementary Fig. 5 Survival impact according to each cut-off value of CRM in the validation cohort. a. Recurrence-free survival. b.

Overall survival.